Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

Abstract

It is known that radiation activates the phosphoinositol-3 kinase (PI3K)/Akt pathway and that inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy. Mammalian target of rapamycin (mTOR) is a downstream target of Akt, and we hypothesized that irradiation activates mTOR signaling in both glioma and endothelial cells (ECs) and that radiosensitization results from inhibiting mTOR signaling. mTOR inhibitors, rapamycin and RAD001 (everolimus) were found to radiosensitize vascular ECs, but failed to sensitize glioma cells as determined by clonogenic assay. Therefore, we investigated the anti-angiogenic effects of mTOR inhibitors. Increased phospho-mTOR protein was detected in irradiated human umbilical vein endothelial cells (HUVEC), but not in GL261 glioma cells. Phospho-S6, a biomarker for mTOR signaling, was also found to be induced following irradiation in HUVEC and this effect was inhibited by PI3K or mTOR inhibitors. Significant increase in cleaved caspase 3 was detected when Rad001 was combined with radiation. Endothelial tube formation was significantly diminished following treatment with rapamycin and 3 Gy of radiation. Histological sections of GL261 tumors from mice showed a greatly reduced vascular density when treated with RAD001 and radiation. Power Weighted Doppler of glioma xenografts in mice showed a significant reduction in vasculature and blood flow compared with mice treated with 3 Gy or RAD001 alone. We conclude that irradiation activates mTOR signaling in vascular endothelium and that rapamycin and RAD001 increased apoptosis of ECs in response to radiation. To the authors' best knowledge this is the first study which demonstrates that mTOR inhibitors may be a way to target the vasculature by radiosensitizing the vascular endothelium resulting in better tumor control as seen in experiments demonstrating increased tumor growth delay in mice treated with rapamycin with radiation compared with mice treat with either treatment alone. We conclude that mTOR inhibitors have increased efficacy as antiangiogenics when combined with radiation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

HUVEC:

human umbilical vein endothelial cells

VEGF:

vascular endothelial growth factor

PTEN:

phosphate and tensin homologue deleted on chromosome 10

PI3K:

phosphoinositol-3 kinase

mTOR:

mammalian target of rapamycin

References

  • Beamish H, Williams R, Chen P, Khanna KK, Hobson K, Watters D, Shiloh Y and Lavin M . (1996). Oncogene, 13, 963–970.

  • Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G and Lane HA . (2004). Cancer Res., 64, 252–261.

  • Chakravarti A, Chakladar A, Delaney MA, Latham DE and Loeffler JS . (2002). Cancer Res., 62, 4307–4315.

  • Chen J, Zheng XF, Brown EJ and Schreiber SL . (1995). Proc. Natl. Acad. Sci. USA, 92, 4947–4951.

  • Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M and Bookstein R . (1999). Cancer Res., 59, 2318–2323.

  • Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO and Krisch RE . (1993). J. Natl. Cancer Inst., 85, 704–710.

  • Dennis PB, Pullen N, Kozma SC and Thomas G . (1996). Mol. Cell. Biol., 16, 6242–6251.

  • Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK and Houghton PJ . (1994). Cancer Res., 54, 903–907.

  • Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC and Houghton PJ . (2002). J. Biol. Chem., 277, 13907–13917.

  • Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C and von Deimling A . (1998). Oncogene, 16, 2259–2264.

  • Dumont FJ, Staruch MJ, Grammer T, Blenis J, Kastner CA and Rupprecht KM . (1995). Cell Immunol., 163, 70–79.

  • Edwards E, Geng L, Tan J, Onishko H, Donnelly E and Hallahan DE . (2002). Cancer Res., 62, 4671–4677.

  • Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D and Haas-Kogan DA . (2002). Clin. Cancer Res., 8, 1100–1106.

  • Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL and Sarkaria JN . (2002). Cancer Res., 62, 7291–7297.

  • Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM and Dalla-Favera R . (1991). Proc. Natl. Acad. Sci. USA, 88, 5413–5417.

  • Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H and Hallahan DE . (2001). Cancer Res., 61, 2413–2419.

  • Gingras AC, Raught B and Sonenberg N . (2001). Genes Dev., 15, 807–826.

  • Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW and Geissler EK . (2002). Nat. Med., 8, 128–135.

  • Hochberg FH and Pruitt A . (1980). Neurology, 30, 907–911.

  • Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE and Fuller GN . (2000). Nat. Genet., 25, 55–57.

  • Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence Jr JC and Houghton PJ . (1998). Mol. Pharmacol., 54, 815–824.

  • Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT and Houghton PJ . (1999). Cancer Res., 59, 886–894.

  • Huang S and Houghton PJ . (2001). Drug Resist. Update, 4, 378–391.

  • Huang S and Houghton PJ . (2003). Curr. Opin. Pharmacol., 3, 371–377.

  • Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T and Houghton PJ . (2001). Cancer Res., 61, 3373–3381.

  • Landis SH, Murray T, Bolden S and Wingo PA . (1998). CA Cancer J. Clin., 48, 6–29.

  • Lang FF, Miller DC, Koslow M and Newcomb EW . (1994). J. Neurosurg., 81, 427–436.

  • Leon SP, Folkerth RD and Black PM . (1996). Cancer, 77, 362–372.

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R . (1997). Science, 275, 1943–1947.

  • Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA and Sellers WR . (2004). Nat. Med., 10, 594–601.

  • Munafo DB and Colombo MI . (2001). J. Cell Sci., 114, 3619–3629.

  • Nave BT, Ouwens M, Withers DJ, Alessi DR and Shepherd PR . (1999). Biochem. J., 344, 427–431.

  • Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M and Miller DC . (1993). Brain Pathol., 3, 229–235.

  • Raught B, Gingras AC and Sonenberg N . (2001). Proc. Natl. Acad. Sci. USA, 98, 7037–7044.

  • Salazar OM and Rubin P . (1976). Int. J. Radiat. Oncol. Biol. Phys., 1, 627–637.

  • Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS and Pieper RO . (2001). Cancer Res., 61, 6674–6678.

  • Tan J and Hallahan DE . (2003). Cancer Res., 63, 7663–7667.

  • Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J, Owens G, Ransohoff 2nd J, Robertson JT, Shapiro WR, Smith Jr KR, Wilson CB and Strike TA . (1980). N. Engl. J. Med., 303, 1323–1329.

  • Wallner KE, Galicich JH, Krol G, Arbit E and Malkin MG . (1989). Int. J. Radiat. Oncol. Biol. Phys., 16, 1405–1409.

  • Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK and Durden DL . (2001). Proc. Natl. Acad. Sci. USA, 98, 4622–4627.

  • Wesseling P, Ruiter DJ and Burger PC . (1997). J. Neurooncol., 32, 253–265.

  • Wick W, Furnari FB, Naumann U, Cavenee WK and Weller M . (1999). Oncogene, 18, 3936–3943.

  • Yu Y and Sato JD . (1999). J. Cell Physiol., 178, 235–246.

Download references

Acknowledgements

This study was supported in part by DOD PC031161(BL), BC 030542 (BL), NIH training grant T-32 CA93240, Vanderbilt Discovery Grant, and a grant from MARF. We thank Dr Heidi Lane for providing Rad001 and reviewing our manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bo Lu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shinohara, E., Cao, C., Niermann, K. et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24, 5414–5422 (2005). https://doi.org/10.1038/sj.onc.1208715

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208715

Keywords

This article is cited by

Search

Quick links